

Detailed contents

Symbols and abbreviations *xix*

| | |
|-------------------------------------------------------------|----------|
| 1 Aetiology and pathophysiology | 1 |
| Haemodynamics | 2 |
| Haemodynamics in hypertension | 4 |
| Central versus peripheral blood pressure | 6 |
| Physiology and pathophysiology of blood pressure regulation | 8 |
| Role of the autonomic nervous system | 10 |
| Role of the kidneys | 16 |
| Interplay between autonomic and renal mechanisms | 20 |
| Vascular structure and function in essential hypertension | 22 |
| Large arteries | 26 |
| Genetics of essential hypertension | 28 |
| Environmental influences on blood pressure | 30 |
| Physical activity | 34 |
| Diet | 36 |
| Salt intake | 38 |
| Potassium intake | 40 |
| Alcohol | 41 |
| Stress | 42 |
| Obesity | 44 |
| Experimental models of hypertension | 46 |

| | |
|---------------------------------|-----------|
| 2 Essential hypertension | 49 |
| <i>Background</i> | |
| Prevalence and incidence | 50 |
| Isolated systolic hypertension | 52 |
| Systolic/diastolic hypertension | 58 |
| Isolated diastolic hypertension | 59 |
| <i>Assessment</i> | |
| History | 60 |
| Examination | 62 |

xiv DETAILED CONTENTS

Blood pressure measurement 64
Assessing end-organ damage 66
Investigations in hypertension 68
Biochemistry
Basic biochemistry 70
Renin and aldosterone 72
Dipstick urinalysis 73
Physiological measurements
Electrocardiography 74
Home blood pressure 78
24-hour ambulatory blood pressure monitoring 80
Echocardiography 83
Management
Prognosis and risk stratification 84
Non-pharmacological management
Non-pharmacological management: background 88
Salt 90
Dietary intervention, weight loss, and exercise 92
Alcohol 94
Other methods 97
Pharmacological management
Pharmacological management: background 98
Compliance 99
Stepped care versus combination therapy 100
Targets and evidence basis 101
Treatment algorithms 102
Resistant hypertension 106
Hypertensive emergencies 108

3 Specific investigations for secondary hypertension 111

Introduction 112
Phaeochromocytoma
Urine catecholamines and metanephrines 114
Plasma catecholamines and metanephrines 116
Dynamic testing 118
Clonidine suppression test 120
Pentolinium suppression test 121

Conn's syndrome
 Fludrocortisone suppression test 122
 Saline suppression test 122
Imaging
 Computed tomography 123
 Magnetic resonance imaging 124
 Nuclear medicine: adrenal 126
 Nuclear medicine: kidney 130
 Interventional radiology 132

4 Secondary hypertension 135

Vascular
 Co-arcuation of the aorta 136
 Renal artery stenosis 138
Endocrine
 Hyperaldosteronism 144
 Conn's syndrome 148
 Bilateral adrenal hyperplasia 150
 Cushing's syndrome 151
 Pheochromocytoma 152
 Hyperparathyroidism 156
 Hyperthyroidism 157
Renal
 Renal parenchymal disease 158
 Adult polycystic kidney disease 160
 Renal tumours 162
Drugs
 Liquorice 163
 Alcohol 164
 Oral contraceptive pill 165
 Steroids 165
 Non-steroidal anti-inflammatory drugs 166
 Immunosuppressives 166
 Vascular endothelial growth factor inhibitors 166
 Monoamine oxidase inhibitors 167
 Cocaine 168
 Heavy metals 168

| | |
|------------------------------------------------|------------|
| 5 Monogenic syndromes | 169 |
| Introduction | 170 |
| Pathophysiology | 172 |
| Apparent mineralocorticoid excess | 174 |
| Mineralocorticoid receptor-activating mutation | 175 |
| Gordon's syndrome | 176 |
| Hypertensive congenital adrenal hyperplasia | 177 |
| Glucocorticoid remediable aldosteronism | 178 |
| Liddle's syndrome | 179 |
| Bartter's syndrome | 180 |
| Gitelman's syndrome | 182 |
| <hr/> | |
| 6 Special populations | 183 |
| Pregnancy | 184 |
| Pregnancy: chronic hypertension | 188 |
| Pregnancy: gestational hypertension | 189 |
| Pregnancy: pre-eclampsia | 190 |
| Diabetes | 196 |
| The elderly | 200 |
| Children | 204 |
| Post-stroke | 208 |
| Transplant patients | 210 |
| <hr/> | |
| 7 Antihypertensive drugs | 211 |
| Angiotensin-converting enzyme inhibitors | 212 |
| Angiotensin receptor antagonists | 214 |
| Beta-blockers | 216 |
| Calcium-channel antagonists | 218 |
| Thiazide diuretics | 222 |
| Potassium-sparing diuretics | 226 |
| Aldosterone antagonists | 228 |
| Alpha-blockers | 230 |
| Renin inhibitors | 232 |
| Central sympatholytics | 234 |
| Sodium nitroprusside | 235 |
| Minoxidil | 235 |
| Hydralazine | 236 |

Nitrates 237
 Other agents 238

8 Hypertension in the 21st century 239

Prevention 240
 Cardiovascular risk assessment 241
 Dilemmas in modern management 242
 Emerging concepts: arterial stiffness 244
 Useful websites 247
 Clinical trials: a glossary 248

Index 305